Although, the HH pathway emerged as one of the most attractive therapeutic target for this cancer entity, clinical applications of SMO antagonists are restricted because of their poor systemic bioavailability, development of drug-resistance mutations, and additional GLI activation via noncanonical pathways. The gene discussed is GLI1; the disease is cancer.